FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes


You May Also Like

Inovio Pharmaceuticals Reports 2018 Third Quarter Financial Results

PLYMOUTH MEETING, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a ...

Summit Outline Phase 3 Programme for Novel CDI Antibiotic Ridinilazole

Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT OUTLINES PHASE 3 PROGRAMME ...